Patents by Inventor Marie Kosco-Vilbois

Marie Kosco-Vilbois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD47 antibodies and methods of use thereof
    Patent number: 11840553
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: December 12, 2023
    Assignee: Novimmune SA
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
  • Anti-IL-6/IL-6R antibodies and methods of use thereof
    Patent number: 11613582
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: March 28, 2023
    Assignee: NovImmune S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20220324994
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: November 15, 2021
    Publication date: October 13, 2022
    Inventors: Francois ROUSSEAU, Jeremy LOYAU, Nicolas FISCHER, Greg ELSON, Marie KOSCO-VILBOIS
  • Anti-CD47 antibodies and methods of use thereof
    Patent number: 11059910
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 13, 2021
    Assignee: NovImmune SA
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10982004
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 20, 2021
    Assignee: NovImmune SA
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210009691
    Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FRI through FR4 or CDRI through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: July 31, 2020
    Publication date: January 14, 2021
    Inventors: Bernard MACH, Yann DEAN, Marie KOSCO-VILBOIS, Greg ELSON, Nicolas FISCHER, Olivier LEGER
  • ANTI-IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200354461
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 12, 2020
    Applicant: NovImmune, S.A.
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GUILHOT
  • Anti-IL-6/IL-6R antibodies and methods of use thereof
    Patent number: 10759862
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 1, 2020
    Assignee: Novimmune, S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Anti-CD3 antibodies and methods of use thereof
    Patent number: 10759858
    Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 1, 2020
    Assignee: NovImmune S.A.
    Inventors: Bernard Mach, Yann Dean, Marie Kosco-Vilbois, Greg Elson, Nicolas Fischer, Olivier Leger
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20200239566
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Application
    Filed: August 15, 2019
    Publication date: July 30, 2020
    Inventors: Marie KOSCO-VILBOIS, Katrien DEGRAAF, Thierry BERNEY, Laurianne Santa GIOVANNONI, Domenic BOSCO
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20200207866
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: July 19, 2019
    Publication date: July 2, 2020
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10421809
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: September 24, 2019
    Assignee: NovImmune SA
    Inventors: Marie Kosco-Vilbois, Katrien De Graaf, Thierry Berney, Laurianne Santa Giovannoni, Domenic Bosco
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10400044
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: September 3, 2019
    Assignee: NovImmune SA
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180355065
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 13, 2018
    Applicant: NovImmune S.A.
    Inventors: Krzysztof MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180291115
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 11, 2018
    Inventors: Krzysztof MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180291116
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 11, 2018
    Inventors: Krzysztof MASTERNAK, Nicolas FISCHER, Francois ROUSSEAU, Elie DHEILLY, Marie KOSCO-VILBOIS
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180194842
    Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 12, 2018
    Inventors: Bernard MACH, Yann DEAN, Marie KOSCO-VILBOIS, Greg ELSON, Nicolas FISCHER, Olivier LEGER
  • ANTI-IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180086839
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 29, 2018
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GULHOT
  • Anti-CD3 antibodies and methods of use thereof
    Patent number: 9850304
    Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: December 26, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Bernard Mach, Yann Dean, Marie Kosco-Vilbois, Greg Elson, Nicolas Fischer, Olivier Leger
  • Anti-IL-6/IL-6R antibodies
    Patent number: 9828430
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 28, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot